Kidney Cancer Coverage from Every Angle

FDA Grants Regulatory Approval to Expand Use of Cryoablation to Treat Kidney Cancer

By: JNCCN 360 Staff
Posted: Monday, January 6, 2020

On December 22, Israel’s IceCure Medical said it received U.S. Food and Drug Administration (FDA) regulatory approval to expand the use of its cryoablation technology to treat benign and cancerous kidney and liver tumors. This treatment uses special needles to inject liquid nitrogen to freeze and destroy tumors without the need for surgery. Until now, cryoablation technology had focused on the treatment of breast tumors.

The FDA also approved the company’s new MultySense system, which has three probes; its earlier system had one needle. With this new system, the company expects to be able to treat larger tumors or a few different tumors at the same time of treatment. The new system is expected to be launched at the end of 2021.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.